There is a newer version
of
this Section
2020 Utah Code
Title 26 - Utah Health Code
Chapter 61 - Cannabinoid Research Act
Part 1 - General Provisions
Section 102 - Definitions.
Universal Citation: UT Code § 26-61-102 (2020)
Effective 3/25/2017
26-61-102. Definitions.
As used in this chapter:
Enacted by Chapter 398, 2017 General Session
Technically renumbered to avoid duplication of section number also enacted in HB345, Chapter 413.
26-61-102. Definitions.
As used in this chapter:
- (1) "Approved study" means a medical research study:
- (a) the purpose of which is to investigate the medical benefits and risks of cannabinoid products; and
- (b) that is approved by an IRB.
- (2) "Board" means the Cannabinoid Product Board created in Section 26-61-201.
- (3) "Cannabinoid product" means the same as that term is defined in Section 58-37-3.6.
- (4) "Cannabis" means the same as that term is defined in Section 58-37-3.6.
- (5) "Expanded cannabinoid product" means the same as that term is defined in Section 58-37-3.6.
- (6) "Institutional review board" or "IRB" means an institutional review board that is registered for human subject research by the United States Department of Health and Human Services.
Enacted by Chapter 398, 2017 General Session
Technically renumbered to avoid duplication of section number also enacted in HB345, Chapter 413.
Disclaimer: These codes may not be the most recent version. Utah may have more current or accurate information. We make no warranties or guarantees about the accuracy, completeness, or adequacy of the information contained on this site or the information linked to on the state site. Please check official sources.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
